SciClone Pharmaceuticals Inc (SCLN)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014376)
◆英語タイトル:SciClone Pharmaceuticals Inc (SCLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014376
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:47
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
SciClone Pharmaceuticals Inc (SciClone) develops and commercializes products for the treatment of cancer, cardiovascular disorders and infectious diseases. The company’s lead product, Zadaxin (thymalfasin), an immunostimulatory agent approved for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), sepsis, certain cancers, and as an immune system enhancer. SciClone also markets other pharmaceutical products in China including DC Bead, a product for the embolization of malignant hypervascularized tumors. It also has several drug candidates in various clinical development states intended for the treatment of cancer and cardiovascular diseases. The company has presence in Beijing and Shanghai in China; Hong Kong and Vietnam. SciClone is headquartered in Foster City, California, the US.

SciClone Pharmaceuticals Inc (SCLN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 12
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 13
Licensing Agreements 14
SciClone Pharma Enters into Licensing Agreement with Soligenix 14
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 15
Phosplatin Therapeutics Enters into Licensing Agreement with SciClone Pharma 16
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 17
Medicines Company Enters into Licensing Agreement with SciClone 18
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 20
SciClone Pharma And Zensun (Shanghai) Science & Technology Enter Into Licensing Agreement For Neucardin 21
Equity Offering 23
SciClone Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 23
Acquisition 25
GL Capital Led Consortium Acquires SciClone Pharma for up to USD605 Million 25
SciClone Pharma Acquires NovaMed Pharma 27
SciClone Pharmaceuticals Inc – Key Competitors 29
SciClone Pharmaceuticals Inc – Key Employees 30
SciClone Pharmaceuticals Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Aug 09, 2017: SciClone Reports Second Quarter 2017 Financial Results 32
May 10, 2017: SciClone Reports First Quarter 2017 Financial Results 34
Mar 06, 2017: SciClone Reports 2016 Financial Results And 2017 Outlook 36
Nov 09, 2016: SciClone Reports Third Quarter 2016 Financial Results 38
Aug 09, 2016: SciClone Reports Second Quarter 2016 Financial Results 40
May 10, 2016: SciClone Reports First Quarter 2016 Financial Results 42
Mar 10, 2016: SciClone Reports 2015 Financial Results 43
Jan 11, 2016: SciClone Announces Preliminary 2015 Revenue 45
Other Significant Developments 46
Jul 19, 2016: SciClone Provides Update On Strategic Review Process 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
SciClone Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
SciClone Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Soligenix Enters Into Co-Marketing Agreement With SciClone Pharma For SGX942 12
Sanofi-Aventis Expands Co-Promotion Agreement with NovaMed Pharma 13
SciClone Pharma Enters into Licensing Agreement with Soligenix 14
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 15
Phosplatin Therapeutics Enters into Licensing Agreement with SciClone Pharma 16
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 17
Medicines Company Enters into Licensing Agreement with SciClone 18
SciClone Pharma Enters Into Licensing Agreement With Taiwan Liposome For ProFlow 20
SciClone Pharma And Zensun (Shanghai) Science & Technology Enter Into Licensing Agreement For Neucardin 21
SciClone Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 23
GL Capital Led Consortium Acquires SciClone Pharma for up to USD605 Million 25
SciClone Pharma Acquires NovaMed Pharma 27
SciClone Pharmaceuticals Inc, Key Competitors 29
SciClone Pharmaceuticals Inc, Key Employees 30
SciClone Pharmaceuticals Inc, Subsidiaries 31

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ SciClone Pharmaceuticals Inc (SCLN)-製薬・医療分野:企業M&A・提携分析(SciClone Pharmaceuticals Inc (SCLN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆